Condition: Advanced Cancer · Solid Tumor · Haematological Malignancy · Sponsor: Helsinki University Central Hospital
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
This description comes directly from the study's public registry record.
Tanja Juslin · +358405597415 · tanja.juslin@hus.fi
Always discuss trial participation with your own doctor first.
| Turku University Hospital Cancer Centre | Turku, Southwest Finland, Finland | Recruiting |
| Helsinki University Hospital Comprehensive Cancer Center | Helsinki, Uusimaa, Finland | Recruiting |
| Kuopio University Hospital | Kuopio, Finland | Recruiting |
| Oulu University Hospital OYS Cancer Center | Oulu, Finland | Recruiting |
| Tampere University Hospital Department of Oncology | Tampere, Finland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05159245